11/20
04:15 pm
lxrx
Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]
Neutral
Report
Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]
11/20
04:05 pm
lxrx
Lexicon Appoints Ivan H. Cheung to Board of Directors
Low
Report
Lexicon Appoints Ivan H. Cheung to Board of Directors
11/18
08:35 am
lxrx
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]
11/14
08:12 am
lxrx
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago [Yahoo! Finance]
Low
Report
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago [Yahoo! Finance]
11/14
08:00 am
lxrx
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
Low
Report
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
11/13
08:06 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/13
08:05 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/13
02:32 am
lxrx
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
11/12
04:12 pm
lxrx
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
04:05 pm
lxrx
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
11/11
07:33 am
lxrx
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
Neutral
Report
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
11/6
08:28 pm
lxrx
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates [Yahoo! Finance]
Medium
Report
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates [Yahoo! Finance]
11/6
08:00 am
lxrx
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Medium
Report
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
11/5
04:05 pm
lxrx
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
Medium
Report
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
11/5
09:48 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/5
08:00 am
lxrx
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
Medium
Report
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024
11/4
08:00 am
lxrx
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
Low
Report
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss
10/31
06:59 pm
lxrx
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease [Yahoo! Finance]
High
Report
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease [Yahoo! Finance]
10/31
06:54 pm
lxrx
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
High
Report
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
10/30
09:25 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/30
08:00 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
10/23
09:00 am
lxrx
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
Medium
Report
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
10/23
08:18 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/22
08:00 am
lxrx
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Low
Report
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
10/18
03:32 pm
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was given a new $6.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was given a new $6.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.